Gilead Sciences, Inc. (GILD) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - General Branche. Der Hauptsitz des Unternehmens ist in Foster City, CA, United States. Der aktuelle CEO ist Daniel O'Day.
GILD hat IPO-Datum 1992-01-22, 17,600 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $174.33B.
Gilead Sciences, Inc. is a biopharmaceutical company headquartered in Foster City, California, that discovers, develops, and commercializes innovative medicines addressing unmet medical needs across the United States, Europe, and international markets. The company's portfolio spans multiple therapeutic areas, including HIV/AIDS treatment with leading antiretroviral products such as Biktarvy and Truvada, hepatitis C and liver disease management through Epclusa and Harvoni, oncology and cell therapy with products like Yescarta and Trodelvy, and other critical care areas including pulmonary arterial hypertension and serious fungal infections. Gilead also gained prominence for Veklury, its antiviral treatment for COVID-19. The company maintains strategic collaboration agreements with numerous leading biopharmaceutical and research organizations to advance its pipeline and expand its therapeutic capabilities.
